KALA BIO INC
KALANASDAQ🏆 #5102 by market capEarnings Nov 17 · PostUS Equity
$0.18▲ $0.00 (+0.56%)
Market closed · at closeTrack KALA
Get earnings, price moves & breaking news on Telegram
24h▲ 0.6%
7d▼ 4.9%
14d▼ 8.1%
30d▼ 64.4%
ytd▼ 99.4%
1y▼ 99.6%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.18 – $0.18
- 52-Week Range
- $0.11 – $95.50
- Volume (shares)
- 300
- Avg Volume (shares)
- —
- Shares Outstanding
- 19.3M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-135.92
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −100.0%
KALA BIO INC
KALAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
34.2%▼ −46.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$39M▼ −3.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$32M▲ +8.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
0▼ −100.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$11M YoY
StockOtter · stockotter.spaceAbout KALA BIO INC
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.